Vas Narasimhan

Novartis investors demand M&A overhaul after trial failures

Novartis shareholders are stepping up scrutiny of the Swiss drugmaker's dealmaking strategy after back-to-back clinical trial failures sent its stock to a record single-day decline, wiping nearly $30 billion off its market value and erasing all gains since the start…